Evidence map›Paper›PMID 32635142›Full record

ArticlePharmaceutics2020

A Mixed-Surface Polyamidoamine Dendrimer for In Vitro and In Vivo Delivery of Large Plasmids.

Bhairavi Srinageshwar, Maria Florendo, Brittany Clark, Kayla Johnson, Nikolas Munro, Sarah Peruzzaro, Aaron Antcliff, Melissa Andrews, Alexander Figacz, Douglas Swanson and 3 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Bhairavi SrinageshwarCollege of Medicine, Central Michigan University, Mount Pleasant, MI 48859, USA.ORCID 0000-0002-8763-545X
Maria FlorendoCollege of Medicine, Central Michigan University, Mount Pleasant, MI 48859, USA.
Brittany ClarkDepartment of Chemistry and Biochemistry, Central Michigan University, Mount Pleasant, MI 48859, USA.
Kayla JohnsonDepartment of Chemistry and Biochemistry, Central Michigan University, Mount Pleasant, MI 48859, USA.
Nikolas MunroProgram in Neuroscience, Central Michigan University, Mount Pleasant, MI 48859, USA.
Sarah PeruzzaroProgram in Neuroscience, Central Michigan University, Mount Pleasant, MI 48859, USA.
Aaron AntcliffCollege of Medicine, Central Michigan University, Mount Pleasant, MI 48859, USA.
Melissa AndrewsCollege of Medicine, Central Michigan University, Mount Pleasant, MI 48859, USA.
Alexander FigaczCollege of Medicine, Central Michigan University, Mount Pleasant, MI 48859, USA.
Douglas SwansonDepartment of Chemistry and Biochemistry, Central Michigan University, Mount Pleasant, MI 48859, USA.
Gary L DunbarProgram in Neuroscience, Central Michigan University, Mount Pleasant, MI 48859, USA.
Ajit SharmaDepartment of Chemistry and Biochemistry, Central Michigan University, Mount Pleasant, MI 48859, USA.
Julien RossignolCollege of Medicine, Central Michigan University, Mount Pleasant, MI 48859, USA.ORCID 0000-0002-8662-0547
Central Michigan University · US

Funding

Non-Invasive Nanoparticle Platform for Tool Delivery to the BrainR21EY030012 · NEI · CENTRAL MICHIGAN UNIVERSITY · PI HOCHGESCHWENDER, UTE H, ROSSIGNOL, JULIEN · 2019 to 2019
$520k
NEI NIH HHS R21 EY030012
6 · The paper itself

Abstract

Drug delivery to the brain is highly hindered by the presence of the blood-brain barrier (BBB), which prevents the entry of many potential drugs/biomolecules into the brain. One of the current strategies to achieve gene therapy for neurodegenerative diseases involves direct injection of a viral vector into the brain. There are various disadvantages of viral vectors, including limitations of cargo size and safety concerns. Nanomolecules, such as dendrimers, serve as an excellent alternative to viral delivery. In this study, as proof-of-concept, we used a surface-modified dendrimer complex and delivered large plasmids to cells in vitro and in vivo in healthy rats via intracranial injection. The dendrimers were biodegradable by chemicals found within cells and toxicity assays revealed that the modified dendrimers were much less toxic than unmodified amine-surface dendrimers. As mentioned in our previous publication, these dendrimers with appropriately modified surfaces are safe, can deliver large plasmids to the brain, and can overcome the cargo size limitations associated with viral vectors. The biocompatibility of this dendritic nanomolecule and the ability to finely tune its surface chemistry provides a gene delivery system that could facilitate future in vivo cellular reprograming and other gene therapies.

Indexed as

gene deliveryglial cellslarge plasmidmixed-surface polyamidoamine dendrimersSox2

Identifiers

PMID32635142
PMCPMC7407876
OpenAlexW3039643396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.